In immediate-release film-coated tablet manufacture, atorvastatin calcium trihydrate is handled as a pH-sensitive, low-dose active whose label claim is expressed as atorvastatin free acid. The salt-to-free-acid conversion is a fixed formula calculation: the molecular ratio of the trihydrate to the free acid is 1.083, so the 10 mg, 20 mg, 40 mg, and 80 mg strengths require 10.83 mg, 21.66 mg, 43.32 mg, and 86.64 mg of atorvastatin calcium trihydrate, respectively. The active proportion in the tablet core is not defined by the monograph; it is the arithmetical result of the converted API mass divided by the final core mass, and it may range from approximately 2% w/w to 22% w/w across commercial core weights. Core formulation ratios must protect the hydroxy acid anion from acid-catalysed lactonization to the pharmacologically inactive lactone; when an alkaline pH modifier is required, it is included at 0.5–2.0% w/w of the core, with the dried granulate pH held above 6.0. Crospovidone or croscarmellose sodium is dispensed at 2–5% w/w as the disintegrant, and magnesium stearate is restricted to 0.5–1.5% w/w because higher lubricant levels reduce compact tensile strength and increase friability. The downstream process is dominated by dry roller compaction or low-moisture wet granulation, not direct compression; the crystalline API exhibits flow and compactibility constraints that make direct compression segregation-prone. Roller-compacted ribbons are milled through a cone mill fitted with a 0.8 mm or 1.0 mm screen, blended in a bin blender, and compressed on a rotary tablet press with precompression enabled. When precompression is omitted or final compression is raised without sufficient dwell, production batches show capping and lamination; published data for a universal compression window is limited because tooling geometry and press model determine the safe range. Aqueous film coating is applied to a 3–5% w/w weight gain under bed temperature conditions that avoid dehydration of the crystalline trihydrate. Release testing is performed against the current USP Atorvastatin Calcium Tablets monograph, USP <711> dissolution testing, USP <905> uniformity of dosage units, ICH Q3B(R2) degradation products, and 21 CFR 211.165 finished-product testing. The terminal finished product class is the immediate-release film-coated tablet in 10 mg, 20 mg, 40 mg, and 80 mg strengths, packaged in HDPE bottles with desiccant or in aluminium-aluminium blister cavities.

What Happens to Dose Uniformity in Low-Fill Sachet Granules?

When the dosage form is changed from a tablet core to a single-dose sachet granule for patients who cannot swallow intact tablets, the central formulation risk is not dissolution but the relative standard deviation of the low-dose API in a large hydrophilic fill matrix. The label dose is typically 10 mg or 20 mg as atorvastatin free acid, corresponding to 10.83 mg or 21.66 mg of atorvastatin calcium trihydrate. Because the final sachet fill mass is governed by form-fill-seal metering and palatability, the active concentration is frequently below 1% w/w; direct addition of the API into the final blend without a pre-blend would produce content-uniformity failure. The addition ratio therefore consists of a staged geometric dilution: the milled API is pre-blended with mannitol or sorbitol at an active-to-diluent ratio between 1:5 and 1:20, screened, and then diluted in the final batch. A suspending agent is included at 0.5–2.0% w/w, and an anti-caking agent is added only when the sachet is to be stored in high-humidity markets. Downstream processing uses low-shear tumble blending after dry milling of the API through a 0.5 mm screen; if flow properties are poor, roller compaction is introduced before final blending. The granulate is filled on a continuous form-fill-seal line with gravimetric checkweighing at ±2% of target fill weight, and moisture is controlled to NMT 2.0% LOD to avoid sticking. Compliance for this configuration is not anchored to a harmonised monograph for atorvastatin calcium sachet granules across all major compendia; published data for this specific configuration is limited. Regional release specifications are instead built from USP <905> or Ph.Eur. 2.9.40 for uniformity of dosage units, USP <711> for dissolution, ICH Q3D(R2) for elemental impurities, and 21 CFR 211.110 for in-process blend homogeneity. Terminal finished products are single-dose sachets of oral granules intended for reconstitution or direct administration, and, where regional prescribing permits, granule-filled hard gelatin sprinkle capsules.

Lipid-Based Capsule Filling and the BCS II Solubility Barrier

Atorvastatin calcium is a low-solubility, high-permeability compound, and liquid-filled hard capsules are used when the formulation must reduce the risk of food-related absorption differences. The API is dissolved or suspended in a lipid matrix composed of medium-chain triglycerides, propylene glycol monocaprylate, and polyoxyl-40 hydrogenated castor oil; the drug load is maintained at 5–12% w/w of the fill mass because the equilibrium solubility in the lipid phase at 37°C defines the upper limit and the fill must not exceed 80% of the saturation value to avoid precipitation after capsule shell opening. The lipid phase occupies 40–70% w/w, the surfactant system 15–35% w/w, and a short-chain co-solvent 5–15% w/w of the fill composition. The manufacturing process is carried out on a heated liquid-fill machine with the hopper and filling pump maintained at 38–42°C; continuous stirring is required because viscosity stratification in the fill tank is a known source of fill-weight drift. Hard gelatin capsule shells are conditioned at 35–50% RH before filling to prevent brittle fracture in the band-sealing station. Capsule fill weight is checked periodically against the mass variation criteria of USP <905>, and dissolution is measured with USP <711>. Residual solvent testing follows USP <467> and ICH Q3C(R8) because the lipid premix may contain low-level solvent from the API crystallization step; in-process controls are documented under 21 CFR 211.110. Terminal finished product types are liquid-filled hard gelatin capsules at 10 mg, 20 mg, and 40 mg free acid strengths, with band-sealed caps and desiccant packaging.

When Fixed-Dose Combinations Require Bilayer Compression

Bilayer tablet production for atorvastatin calcium combined with amlodipine besylate or ezetimibe introduces a delamination failure mode that is not present in monotherapy tablets. The atorvastatin layer follows the same free acid to trihydrate conversion of 1.083; for a 10 mg atorvastatin plus 10 mg ezetimibe tablet, the atorvastatin layer contains 10.83 mg of atorvastatin calcium trihydrate and the ezetimibe layer contains 10 mg of ezetimibe, while for amlodipine combinations the amlodipine salt weight is calculated from the besylate equivalent. The layer mass ratio is not a fixed compendial requirement; it is determined by the minimum fill depth and flow of each granulation, but the atorvastatin-containing layer is commonly 55–65% w/w of the total core because the low-dose blend requires sufficient matrix mass for content uniformity. Excipient ratios in the atorvastatin layer mirror the monotherapy tablet: disintegrant at 2–5% w/w, lubricant at 0.5–1.0% w/w, and an alkaline pH modifier if the granulate pH falls below 6.0. The downstream process requires a two-station rotary tablet press with first-layer precompression before the second layer is added. The first layer is compressed lightly to form a defined interfacial surface without glazing; the second layer is then compressed to final hardness. Delamination at the layer interface is the primary in-process failure, caused by insufficient first-layer deaeration, excessive first-layer hardness, or low dwell time. Release testing includes USP <905> for content uniformity, USP <711> for dissolution of both actives, ICH Q3B(R2) for degradation products, and 21 CFR 211.166 for stability commitment. Terminal finished products are fixed-dose combination bilayer tablets containing atorvastatin with ezetimibe or atorvastatin with amlodipine besylate, packaged in moisture-protective blister foil.

Spray-dried amorphous dispersion is the selected route when the BCS II solubility limitation of crystalline atorvastatin calcium must be overcome in an oral intermediate. In this configuration, the API is converted to the free acid equivalent using 1.083 and then dispersed with hypromellose acetate succinate L-grade at a drug:polymer ratio between 1:3 and 1:5, producing an atorvastatin content of 16.7–25.0% w/w in the dried solid dispersion. The feed solution is prepared in acetone or a dichloromethane/ethanol system; the solvent choice is constrained by ICH Q3C(R8) and USP <467> residual solvent limits. Spray drying is performed in a closed-cycle spray dryer with cyclone collection; the inlet and outlet temperatures are set to maintain the powder below the recrystallization onset of the amorphous phase. The collected powder is secondary-dried under vacuum at 40–50°C until the residual solvent concentration meets the selected ICH Q3C(R8) option 2 limit. Because the spray-dried powder has a low bulk density and poor flow, it is roller-compacted or wet-granulated with extragranular excipients before tablet compression or capsule filling. The final blend is controlled by USP <905> and USP <711>, and the manufacturing area is maintained below 30% RH to reduce moisture-induced recrystallization. This route is more thermally complex than crystalline tablet granulation and requires a humidity-controlled intermediate holding step; published data for specific inlet temperature windows is limited because the critical process parameters depend on the selected polymer grade and solvent load. Terminal finished products are amorphous solid dispersion tablets or capsules at 10 mg, 20 mg, and 40 mg free acid strengths.

Preparing Sterile Nanosuspensions for Intravenous Atorvastatin Delivery

Sterile injectable atorvastatin calcium is not harmonised as a parenteral monograph in the major compendia; published data for this specific configuration is limited. When an injectable line is developed for clinical supply, the API is still dispensed as atorvastatin calcium trihydrate and converted to the free acid label claim with the factor 1.083. A 20 mg free acid vial requires 21.66 mg of the trihydrate before assay adjustment; a 10 mg vial requires 10.83 mg. The target reconstituted concentration is usually 2 mg/mL or 5 mg/mL as free acid, but the exact value is constrained by syringeability, osmolality, and subvisible particle counts. The drug is processed by high-pressure homogenization in the presence of a sterile surfactant and a lyoprotectant such as sucrose; the surfactant-to-drug ratio is not fixed by compendial text and must be justified by freeze-thaw and reconstitution stability. If the nanosuspension particle size is below 200 nm, sterile filtration through a 0.22 µm membrane may be used; otherwise, aseptic manufacture without terminal sterilization is required because moist-heat sterilization would destabilize the thermo-sensitive trihydrate and any amorphous fraction. Manufacturing compliance is governed by USP <1> Injections and Implanted Drug Products, USP <85> Bacterial Endotoxins Test, USP <790> Visible Particulates in Injections, USP <788> Particulate Matter in Injections, EU GMP Annex 1 for sterile manufacturing, and 21 CFR 211.113 aseptic processing controls. For a lyophilized presentation, the cake is dried to a moisture content of NMT 1.0% and sealed under vacuum or nitrogen. Terminal finished product types are single-dose vials containing a lyophilized cake for reconstitution or a sterile ready-to-use nanosuspension, produced only where regional regulatory assessment supports the stability and safety data.